In focus
Abbott and Novo Expand Asia Pacific Pact to Distribute Plosbrio Semaglutide
Abbott will commercialise Plosbrio, a second brand of Ozempic developed and manufactured by Novo, across Singapore and other Asia Pacific countries. The companies say the deal aims to widen access to semaglutide for adults with type 2 diabetes.
Read the story